Table 1.

Patient characteristics of TCGA and FUSCC cohorts

Variable	TCGA cohort				FUSCC cohort
	Low purity (N = 203)		High purity (N = 204)		Low purity (N = 17)		High purity (N = 17)
Median purity	64.04%		86.51%		55.63%		81.90%
	N	%	N	%	N	%	N	%
Sex
Male	125	61.58	136	66.67	16	94.12	14	82.35
Female	78	38.42	68	33.33	1	5.88	3	17.65
Age
<56	38	18.72	30	14.71	5	29.41	5	29.41
≥56	163	80.30	173	84.80	12	70.59	12	70.59
Unknown	2	0.99	1	0.49	0	0.00	0	0.00
TNMstage
1	17	8.37	36	17.65	9	52.94	11	64.71
2	65	32.02	57	27.94	8	47.06	6	35.29
3	85	41.87	81	39.71	0	0.00	0	0.00
4	20	9.85	21	10.29	0	0.00	0	0.00
Unknown	16	7.88	9	4.41	0	0.00	0	0.00
pT
1	2	0.99	18	8.82	14	82.35	14	82.35
2	42	20.59	44	21.57	0	0.00	0	0.00
3	88	43.35	91	44.61	0	0.00	1	5.88
4	63	31.03	50	24.51	3	17.65	2	11.76
Unknown	8	3.94	1	0.49	0	0.00	0	0.00
pN
0	56	27.59	63	30.88	7	41.18	10	58.82
1	58	27.59	52	25.49	5	29.41	4	23.53
2	39	19.21	39	19.12	2	11.76	0	0.00
3	40	19.70	41	20.10	3	17.65	3	17.65
Unknown	10	4.93	9	4.41	0	0.00	0	0.00
pM
0	180	88.67	182	89.22	17	100.00	17	100.00
1	15	7.39	12	5.88	0	0.00	0	0.00
Unknown	8	3.94	10	4.90	0	0.00	0	0.00
Histology type
Other adenocarcinoma	178	87.68	194	95.10	15	88.24	16	94.12
Mucinous adenocarcinoma/Signet ring cell carcinoma	23	11.33	9	4.41	2	11.76	1	5.88
Unknown	2	0.99	1	0.49	0	0.00	0	0.00